Press releases

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships …: you can find all the latest Ipsen Group press releases arranged by year.

Filter by date
27 / 02 / 2017 - Paris (France)
Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.
Download ( pdf - 179 kB)
17 / 12 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2016
17 12 2015 PR Ipsen financial agenda 2016 FINAL ( pdf - 31 kB)
01 / 12 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial
Telotristat etiprate obtient des premiers résultats positifs dans une deuxième étude clinique de phase 3 ( pdf - 58 kB)
19 / 11 / 2015 - Paris (France)
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
2015 11 19 PR Ipsen Interprotein peptides Cushing endocrinology FINAL ( pdf - 55 kB)
29 / 10 / 2015 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2015
2015 10 29 PR Q3 & 9-month sales FINAL ( pdf - 125 kB)
28 / 10 / 2015 - Paris (France)
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories
10-28-2015 PR Ipsen Telesta MCNA bladder FINAL ( pdf - 47 kB)
26 / 10 / 2015 - Paris (France)
Ipsen and EpiVax collaborate to produce next generation botulinum toxins
2015 10 26 Ipsen EpiVax next generation toxins ( pdf - 131 kB)
22 / 10 / 2015 - Paris (France)
Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy
2015 10 PR Dysport final results phase III PLL FINAL ( pdf - 99 kB)
19 / 10 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.
Cancer Patients Treated with Lexicon’s Telotristat Etiprate Report Improved Function and Well-Being ( pdf - 60 kB)
01 / 10 / 2015 - Paris (France)
Ipsen announces release of an additional batch of Increlex® in the U.S.
2015 10 01 PR Increlex resupply Corporate FINAL FINAL ( pdf - 74 kB)
01 / 10 / 2015 - Paris (France)
Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen
2015 10 01 PR Stéphane Bessette EVP RH (FINAL FINAL) ( pdf - 72 kB)
29 / 09 / 2015 - Paris (France)
Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.
Lexicon Telotristat Etiprate ( pdf - 60 kB)
31 / 08 / 2015 - Paris (France)
Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)
2015 08 31 Lancet Neurology Dysport ULS EN (FINAL) ( pdf - 79 kB)
03 / 08 / 2015 - Paris (France)
Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs
2015 08 03 telotristat etiprate ph3 results EN ( pdf - 298 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results and 2015 objectives
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
Presentation H1 results FINAL ( pdf - 407 kB)
16 / 07 / 2015 - Paris (France)
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States
PR AUL Approval FINAL ( pdf - 102 kB)
02 / 07 / 2015 - Paris (France)
Ipsen provides an update on 2020 strategy and outlook at Investor Day
PR Strategy 2020 EN - FINAL FINAL ( pdf - 35 kB)
Investor Day 02-07-2015 Presentation Media ( pdf - 966 kB)
03 / 06 / 2015 - Paris (France)
Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans
PR Rachat d'actions EN ( pdf - 168 kB)
02 / 06 / 2015 - Paris (France)
Ipsen confirms its eligibility for PEA-PME
PR PEA PME ( pdf - 92 kB)
29 / 05 / 2015 - Paris (France)
Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015
Communiqué Post-AG 2015 VA ( pdf - 223 kB)
19 / 05 / 2015 - Paris (France)
Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours
PR Ipsen Octreopharm EN - FINAL ( pdf - 80 kB)
29 / 04 / 2015 - Paris (France)
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
PR Q1 15 sales FINAL LAST 2 ( pdf - 81 kB)
16 / 04 / 2015 - Paris (France)
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer
16042015 Ipsen Active Biotech discontinuatio 10Tasq10 FINAL ( pdf - 64 kB)
08 / 04 / 2015 - Paris (France)
Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors
08 04 2015 Ipsen Hannover Medical School PR FINAL ( pdf - 239 kB)
01 / 04 / 2015 - Paris (France)
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
PR 01 04 2015 Cambridge Grand opening and Connecting with creativity EN ( pdf - 72 kB)
09 03 2015 IPSEN_Abstract_book-00 ( pdf - 1 MB)
01 / 04 / 2015 - Paris (France)
Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement
01 04 2015 PR Harvard Ipsen 2015 Research Alliance Agreement ( pdf - 57 kB)
31 / 03 / 2015 - Paris (France)
The Ipsen Group publishes its 2014 Registration document
PR DDR ( pdf - 112 kB)
04 / 03 / 2015 -
Precisions concerning the resupply of Increlex® in the U.S.
Precisions Increlex resupply 150304 ( pdf - 143 kB)
03 / 03 / 2015 - Paris (France)
Ipsen’s 2014 results and 2015 financial objectives
PR FY2014 results -FINAL ( pdf - 264 kB)
02 / 03 / 2015 - Paris (France)
Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
PR appointment Dominique Laymand FINAL ( pdf - 222 kB)
02 / 03 / 2015 - Paris (France)
Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
PR Increlex resupply 3rd batch US FINAL ( pdf - 113 kB)
24 / 02 / 2015 - Paris (France)
Ipsen enters into option agreement to acquire Canbex Therapeutics
24 02 2015 PR Canbex Ipsen Multiple sclerosis- Final FINAL ( pdf - 61 kB)
03 / 02 / 2015 - Paris (France)
Ipsen: sales in the fourth quarter and full year 2014
PR FY14 sales FINAL ( pdf - 198 kB)
26 / 01 / 2015 - Paris (France)
Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
26012015 PR Dysport ALL & PLL ( pdf - 239 kB)
07 / 01 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2015
Ipsen - 2015 financial agenda ( pdf - 25 kB)
16 / 12 / 2014 - Paris (France)
François Garnier appointed Executive Vice President, General Counsel of Ipsen
12 2014 PR François Garnier_Nathalie Joannes General counsel EN ( pdf - 43 kB)
16 / 12 / 2014 - Paris (France)
Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
12 2014 corporate PR Approval Somatuline US FINAL ( pdf - 76 kB)
12 / 12 / 2014 - Paris (France)
Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen
12 12 2014 - PR IBCSG Decapeptyl Breast cancer EN FINAL ( pdf - 54 kB)
28 / 11 / 2014 - Paris (France)
Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
28 11 2014 PR Dysport AUL sBLA FINAL ( pdf - 47 kB)
20 / 11 / 2014 - Paris (France)
Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
RK rev 20 11 2014 PR Ipsen CNRS joint lab ARCHIPEX FINAL ( pdf - 343 kB)
18 / 11 / 2014 - Paris (France)
Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
18 11 2014 PR Ipsen Salk Insitute renewal agreement (FINAL) ( pdf - 298 kB)
06 / 11 / 2014 - Paris (France)
Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
06 11 2014 Press release Otonomy and Ipsen gacyclidine EN ( pdf - 82 kB)
29 / 10 / 2014 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2014
29 10 2014 PR First 9 months 2014 sales ( pdf - 201 kB)
22 / 10 / 2014 - Paris (France)
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
22 10 2014 PR Ipsen Lexicon telotristat etiprate carcinoid syndrom EN ( pdf - 71 kB)
10 / 10 / 2014 - Paris (France)
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
10 10 2014 PR appointment Aymeric Le Chatelier CFO (FINAL) ( pdf - 42 kB)
10 / 10 / 2014 - Paris (France)
Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients
10 10 2014 PR Decapeptyl subcutaneous administration prostate cancer FINAL ( pdf - 51 kB)
02 / 10 / 2014 - Paris (France)
Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities
2014 10 02 PR departure Susheel Surpal FINAL FINAL ( pdf - 38 kB)
27 / 09 / 2014 - Paris (France)
Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress
PR 27092014 TASQ phase II umbrella Final ( pdf - 93 kB)
01 / 09 / 2014 - Paris (France)
Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe
2014 09 01 PR acceptance filing Somatuline GEP NET US EU EN ( pdf - 116 kB)
29 / 08 / 2014 - Paris (France)
Ipsen: 2014 half-year results and 2014 objectives
PR H1 2014 FINAL ( pdf - 791 kB)
Télécharger la présentation ( pdf - 439 kB)
27 / 08 / 2014 - Basking Ridge (USA)
Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014
Télécharger ( pdf - 238 kB)
17 / 07 / 2014 - Paris (France)
New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Download ( pdf - 81 kB)
11 / 07 / 2014 - Paris (France)
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
PR Ipsen - Galderma FINAL ( pdf - 300 kB)
01 / 07 / 2014 - Paris (France)
Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
PR filing Somatuline GEP NET US EU FINAL ( pdf - 94 kB)
04 / 06 / 2014 - Paris (France)
Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014
04 06 2014 PR general shareholders meeting 2014 EN ( pdf - 41 kB)
13 / 05 / 2014 - Paris (France)
Ipsen announces a step forward in the resupply of Increlex® in the U.S.
13 05 2014 PR Increlex resupply US FINAL ( pdf - 66 kB)
30 / 04 / 2014 - Paris (France)
Ipsen’s first quarter 2014 sales
30042014 PR Q1 2014 sales FINAL ( pdf - 184 kB)
12 / 04 / 2014 - Paris (France)
Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
12042014 PR Dysport AUL WCNR EN FINAL EN ( pdf - 101 kB)
11 / 04 / 2014 - Paris (France)
The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research
PR 30th anniversary Fondation Ipsen EN ( pdf - 41 kB)
09 / 04 / 2014 - Paris (France)
Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext
Download ( pdf - 32 kB)
20 / 03 / 2014 - Paris (France)
Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement
PR Mayroy shareholding Ipsen EN FINAL ( pdf - 169 kB)
18 / 03 / 2014 - Paris (France)
Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)
PR DYSPORT NDO - Phase IIa ( pdf - 51 kB)
28 / 02 / 2014 - Paris (France)
Ipsen’s 2013 results and 2014 financial objectives
28 02 2014 PR FY2013 Results_EN ( pdf - 249 kB)
2013 Annual Results Presentation ( pdf - 402 kB)
07 / 02 / 2014 - Paris (France)
Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer
PR Decapeptyl results 3M subcutaneous administation ( pdf - 316 kB)
05 / 02 / 2014 - Paris (France)
Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW
05 02 2014 PR Dysport Next Generation EN ( pdf - 56 kB)
28 / 01 / 2014 - Paris (France)
Ipsen: sales in the fourth quarter and full year 2013
PR FY13 sales ( pdf - 502 kB)
22 / 01 / 2014 - Paris (France)
Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology
PR New Governance US ( pdf - 35 kB)
17 / 01 / 2014 - Paris (France)
Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint
17012014_PR_ELECT_results_ASCO_GI_EN ( pdf - 132 kB)
14 / 01 / 2014 - London (UK) and Paris (France)
Ipsen and GW Pharmaceuticals plc enter into agreement for Ipsen to promote and distribute Sativex® in Latin America
14012014 PR Ipsen GW Pharmaceuticals Sativex Latin America EN ( pdf - 77 kB)
14 / 01 / 2014 - Paris (France)
Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors
14 01 2014 PR NET US ( pdf - 66 kB)
10 / 01 / 2014 - Paris (France)
Jonathan Barnsley joins Ipsen as Executive Vice President, Technical operations
10 01 2014 PR appointment Jonathan Barnsley EN ( pdf - 55 kB)
23 / 12 / 2013 - Paris (France)
Ipsen announces its corporate agenda for 2014
23 12 2013 PF Corporate agenda 2014 EN ( pdf - 50 kB)
18 / 12 / 2013 - Paris (France)
Ipsen prepares for the resupply of Increlex® in Europe
18122013-PR-Increlex-resupply-EU_EN ( pdf - 64 kB)
18 / 12 / 2013 - Paris (France)
Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France
18 12 2013 PR Ipsen-Mayoly-Spindler-France ( pdf - 94 kB)
17 / 12 / 2013 - Paris (France)
Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity
17122013 PR Dysport AUL spasticity EN ( pdf - 75 kB)
12 / 12 / 2013 - Paris (France)
Dominique Brard joins Ipsen as Executive Vice President, Human Resources
2013 12 12 PR Dominique Brard ( pdf - 42 kB)
03 / 12 / 2013 - Paris (France)
The 13th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Brain Crosstalk in Puberty and Adolescence”
PR Brain crosstalk in puberty and adolescence ENG ( pdf - 57 kB)
22 / 11 / 2013 - Paris (France)
The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago, USA)
PR Jean Louis Signoret Prize Jean Decety 2013 EN ( pdf - 32 kB)
06 / 11 / 2013 - Paris (France)
Ipsen initiates a share buy-back program to partially cover its restricted share plans
06 11 2013 PR Restricted share plans EN ( pdf - 41 kB)
30 / 10 / 2013 - Paris (France)
Ipsen: sales in the third quarter and first nine months of 2013
30 10 2013 PR Q3 2013 sales EN ( pdf - 436 kB)
17 / 10 / 2013 - Paris (France)
The 8th Cell Press / Days of Molecular Medicine Global Foundation / Fondation Ipsen meeting in the Exciting Biologies series: “Biology of boundaries”
Download ( pdf - 72 kB)
09 / 10 / 2013 - Lund (Sweden) and Paris (France)
Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study
2013 10 09 TASQ milestone PR ( pdf - 60 kB)
06 / 10 / 2013 - Tokyo (Japan), Paris (France)
PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease
PR-Ipsen-PeptiDream-Collab-Expansion-EN ( pdf - 114 kB)
02 / 10 / 2013 - Paris (France)
New organization project and composition of the Executive Committee to accelerate the implementation of Ipsen’s strategy
PR New organization_EN_2Oct2013 ( pdf - 70 kB)
28 / 09 / 2013 - Paris (France)
Ipsen announces that results from CLARINET® Phase III clinical trial presented at the 2013 European Cancer Congress showed the antiproliferative effect of Somatuline® (lanreotide) 120 mg injection in the treatment of non-functioning gastroentero and pancreatic neuroendocrine tumors (“GEP-NETs”)
PR Results Clarinet ESMO ( pdf - 83 kB)
26 / 09 / 2013 - Paris (France)
Ipsen to relocate US R&D activities to Cambridge, MA in 2014
26 09 2013 PR Move to Cambridge EN ( pdf - 49 kB)
17 / 09 / 2013 - Paris (France)
Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome
PR ELECT primary endpoint EN ( pdf - 71 kB)
30 / 08 / 2013 - Paris (France)
Ipsen: 2013 half-year results and financial objectives
PR H1 2013 results EN ( pdf - 568 kB)
Results H1 2013 ( pdf - 250 kB)
30 / 08 / 2013 - Paris (France)
Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013
PR Dates Late breaking news and Press conference Clarinet EN ( pdf - 42 kB)
15 / 07 / 2013 - Paris (France)
Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology
20130715-PR Syntaxin Ipsen EN ( pdf - 85 kB)
15 / 07 / 2013 - Paris (France)
Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
PR Harvard Ipsen ( pdf - 54 kB)
11 / 07 / 2013 - Paris (France)
Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors (“GEP-NETs”)
PR Clarinet primary endpoint EN ( pdf - 87 kB)
17 / 06 / 2013 -
“PRIMARYS” study Investigators observed clinically relevant results in an investigational Phase III study with Somatuline® Autogel® 120 mg in patients with acromegaly
PR ENDO PRIMARYS Somatuline EN ( pdf - 199 kB)
14 / 06 / 2013 - Paris (France)
Ipsen reorganizes its US neurology platform and confirms its goal to become profitable in the US in 2014
PR Dysport US reorganization final EN ( pdf - 53 kB)
31 / 05 / 2013 - Paris (France)
Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2013
24 05 2013 PR Post Assemble Generale EN ( pdf - 31 kB)
30 / 05 / 2013 - Paris (France)
24 th Neuronal Plasticity Prize of the Fondation Ipsen: Tim V.P. Bliss, Richard G. Morris and Yadin Dudai awarded for their works in the domain of “Mechanisms of memory”
PR_24th Neuronal Plasticity Prize_EN ( pdf - 159 kB)
25 / 04 / 2013 - Paris (France)
Ipsen’s first quarter 2013 sales
2013 04 25 PR Q1 2013 sales ( pdf - 108 kB)
25 / 04 / 2013 - Paris (France)
Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer
2013 04 25 PR Tasquinimod Analysis plan 10TASQ10 FINAL ( pdf - 57 kB)
25 / 04 / 2013 - Paris (France)
Ipsen expects Increlex® supply interruption due to supplier manufacturing issues
2013 04 25 PR Increlex Supply interruption ( pdf - 40 kB)
24 / 04 / 2013 - Paris (France)
Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appointment of a new Director
2013 04 24 PR Appointment Martha Crawford Board of Directors EN ( pdf - 39 kB)
23 / 04 / 2013 - Paris (France)
The 21st Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “New frontiers in social neuroscience”
PR Ipsen Neurosciences New frontiers in Social Neuroscience EN ( pdf - 70 kB)
10 / 04 / 2013 - Tokyo ( Japan ), Paris (France)
Pepti Dream and Ipsen enter into a collaboration for advancing drug discovery efforts for peptides to treat serious disease
04 2013 PR Peptidream Ipsen joint EN ( pdf - 68 kB)
09 / 04 / 2013 - Paris (France)
Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada
PR Ipsen Valeant Dysport Canada aesthetics EN ( pdf - 70 kB)
27 / 03 / 2013 - Paris (France)
The Ipsen Group publishes its 2012 Registration document
PR Registration document 2012 EN ( pdf - 41 kB)
DDR_2012_EN ( pdf - 3 MB)
21 / 03 / 2013 - Paris (France)
Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 to Baxter International
PR Ipsen Closing OBI-1 sale to Baxter ( pdf - 50 kB)
27 / 02 / 2013 - Paris (France)
Ipsen’s 2012 results and 2013 financial objectives
Ipsen FY 2012 results presentation ( pdf - 481 kB)
PR FY2012 Results ( pdf - 386 kB)
27 / 02 / 2013 - Paris (France)
Christel Bories joins Ipsen as Deputy Chief Executive Officer
PR appointment Christel Bories_EN ( pdf - 57 kB)
20 / 02 / 2013 - Paris (France)
Ipsen and Inspiration Biopharmaceuticals announce closing of the IB1001 sale to Cangene Corporation
PR Ipsen Cangene Closing IB1001 FIX EN FINAL ( pdf - 46 kB)
07 / 02 / 2013 - Braintree (Massachusetts, United States) and Ipsen (Paris,France)
Eziclen® / Izinova® a new product for bowel cleansing successfully completed European decentralised registration procedure
PR Ipsen Braintree BLI800 EU approval ( pdf - 40 kB)
06 / 02 / 2013 -
Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Cangene Corporation on IB1001
06022013 PR Ipsen Inspiration Cangene FIX IB1001 EN ( pdf - 38 kB)
30 / 01 / 2013 - Paris (France)
Ipsen’s fourth quarter and full year 2012 sales
2013 30 01 - PR FY2012 sales EN ( pdf - 233 kB)
24 / 01 / 2013 - Paris (France)
Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Baxter International on OBI-1
PR Ipsen OBI-1 Asset Purchase Agreement EN ( pdf - 51 kB)
17 / 01 / 2013 - Paris (France) and Tokyo (Japan)
Teijin Pharma to launch Ipsen’s Somatuline® subcutaneous injection in the treatment of acromegaly and pituitary gigantism in Japan
PR Ipsen Teijin Somatuline launch_joint press release EN ( pdf - 61 kB)
03 / 01 / 2013 - Paris (France)
Ipsen’s corporate agenda for 2013
03012013 PR financial agenda_2013 EN ( pdf - 23 kB)
18 / 12 / 2012 - Dijon (France), Leuven (Belgium), Paris (France)
Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the KU Leuven enter into a research collaboration for advancing drug discovery efforts with Ipsen in Parkinson’s disease
PR Oncodesign Ipsen KU Leuven EN ( pdf - 87 kB)
10 / 12 / 2012 - Paris (France)
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer
PR TasQ full recruitment phase III mCRPC ( pdf - 69 kB)
05 / 12 / 2012 - Paris (France)
The 12nd Colloque Médecine et Recherche of the Fondation IPSEN in the Endocrinology series: “Hormones, intrauterine health and programming”
20121205-PR Hormones, intrauterine health and programming ( pdf - 70 kB)
04 / 12 / 2012 - Paris (France)
The 21th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Cathy Price (University College London, London, UK)
20121204-PR Jean-Louis Signoret Prize 2012 Cathy Price EN ( pdf - 32 kB)
03 / 12 / 2012 - Paris (France)
Ipsen and Galderma increase their collaboration for Dysport® in new territories
PR IPSEN GALDERMA New agreements FINAL ( pdf - 126 kB)
20 / 11 / 2012 - Paris (France) and Cambridge, Mass. (USA)
Ipsen and Inspiration Biopharmaceuticals announce that OBI-1 has received Fast Track designation from FDA for acquired hemophilia A
PR Ipsen Inspiration OBI-1 Fast Track EN ( pdf - 42 kB)
19 / 11 / 2012 - Paris (France)
The 2012 Fondation Ipsen Longevity Prize has been awarded to Prof. Linda Fried for her outstanding work on the frailty syndrome
20121119-PR Longevity Prize 2012 Linda Fried EN ( pdf - 30 kB)
31 / 10 / 2012 - Paris (France)
Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection
31102012_Ipsen Hemophilia ( pdf - 124 kB)
PR Inspiration chapter 11 EN ( pdf - 66 kB)
29 / 10 / 2012 - Paris (France)
Ipsen’s third quarter and first nine months 2012 sales
PR Sales Q3 2012 FINAL DEF ( pdf - 428 kB)
25 / 10 / 2012 - Paris (France)
The 2nd meeting of the series Days of Molecular Medicine – « The Translational Science of Rare Diseases : From Rare to Care »
20121025-PR Fondation Ipsen Days of molecular medicine 2012 EN ( pdf - 27 kB)
19 / 10 / 2012 - Paris (France)
Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications
PR TASQ POC phase II 4 indications EN ( pdf - 62 kB)
03 / 10 / 2012 - Paris (France)
Ipsen provides update on recent agreement with Inspiration
PR Ipsen update Inspiration EN ( pdf - 58 kB)
03 / 10 / 2012 - Paris (France)
Ipsen initiates a phase II “Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod
PR IPSEN Active Biotech TASQ switch maintenance Ph II EN ( pdf - 95 kB)
01 / 10 / 2012 - Paris (France)
Tasquinimod Biomarker Phase II data presented at ESMO 2012
PR TASQ BIOMARKERS ESMO EN ( pdf - 110 kB)
20 / 09 / 2012 - Paris (France)
The 11th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Dr Jeffrey M. Friedman
20120920-PR Endocrine Regulation Prize 2012 EN ( pdf - 30 kB)
10 / 09 / 2012 - Paris (France)
Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US
PR Increlex US EN ( pdf - 67 kB)
28 / 08 / 2012 - Paris (France)
Ipsen’s half-year 2012 Results
PR_H1_2012_EN ( pdf - 731 kB)
1H12-Results- Analyst presentation_0 ( pdf - 502 kB)
21 / 08 / 2012 - Paris (France)
Ipsen and Inspiration Biopharmaceuticals renegotiate strategic partnership agreement
PR_Ipsen_and_Inspiration_renegotiate_strategic_Partnership ( pdf - 76 kB)
25 / 07 / 2012 - Paris (France)
23rd Neuronal Plasticity Prize of the Fondation Ipsen: Catherine Dulac, Michael Meaney and J. David Sweatt awarded for their pioneer works in the domain of “Epigenetic and brain function”
20120725-PR_23rd Neuronal Plasticity Prize_EN ( pdf - 32 kB)
11 / 07 / 2012 - Paris (France)
Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope
PR Ipsen Dreux EN ( pdf - 61 kB)
10 / 07 / 2012 - Paris (France)
Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B
PR_IB1001 Clinical Hold_EN_0 ( pdf - 73 kB)
29 / 06 / 2012 - Paris (France)
Ipsen’s Somatuline® receives marketing approval in Japan for the treatment of acromegaly and pituitary gigantism
PR Ipsen approval Somatuline Japan EN ( pdf - 78 kB)
04 / 06 / 2012 - Lund (Sweden) and Paris (France)
Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer
PR - Ipsen Active Biotech ASCO curtain raiser EN_0 ( pdf - 93 kB)
01 / 06 / 2012 - Paris (France)
Combined Shareholders’ Meeting of IPSEN S.A. held on 1 June 2012
PR Ipsen Post General Assembly meeting EN ( pdf - 31 kB)
21 / 05 / 2012 - Lund (Sweden) and Paris (France
600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study
PR Ipsen Active Biotech TASQ 600 patients EN ( pdf - 69 kB)
18 / 05 / 2012 - Lund (Sweden) and Paris (France)
Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting
PR - Ipsen Active Biotech ASCO curtain raiser EN ( pdf - 63 kB)
11 / 05 / 2012 - Paris (France)
The 10th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Paolo Sassone-Corsi
20120511-PR Endocrine Regulation Prize 2011 EN ( pdf - 32 kB)
03 / 05 / 2012 - Paris (France)
Ipsen’s first quarter 2012 sales
PR_Q1_2012_sales_EN ( pdf - 103 kB)
25 / 04 / 2012 - Paris (France)
Ipsen pursues its development in the United States with the opening of its new commercial headquarters in New Jersey (NJ)
PR Opening New Jersey Offices EN ( pdf - 106 kB)
17 / 04 / 2012 - Paris (France)
Ipsen’s partner, Inspiration Biopharmaceuticals, announces US filing of Biologics License Application (BLA) for IB1001, a recombinant factor IX product for the treatment of hemophilia B
PR Ipsen IB1001 US ( pdf - 34 kB)
03 / 04 / 2012 - Paris (France)
The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “Programmed cells: from basic neuroscience to therapy”
20120403-PR Fondation Ipsen Neurosciences Programmed cells EN ( pdf - 35 kB)
02 / 04 / 2012 - Paris (France)
The Ipsen Group publishes its 2011 Registration document
PR Registration document 2011 EN ( pdf - 25 kB)
28 / 02 / 2012 - Paris (France)
The 27 th Colloque Médecine et Recherche of the Fondation Ipsen in the Alzheimer Disease series: “Proteopathic Seeds and Neurodegenerative Diseases”
20120228-PR Proteopathic Seeds and Neurodegenerative Diseases_EN ( pdf - 68 kB)
24 / 02 / 2012 - Lund (Sweden) and Paris (France)
Active Biotech and Ipsen report Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress
PR Ipsen Active Biotech phase II safety TASQ ( pdf - 31 kB)
02 / 02 / 2012 - Paris (France)
Ipsen’s fourth quarter and full year 2011 sales and other significant developments
FY 2011 Sales Presentation_0 ( pdf - 78 kB)
PR-FY11 Sales-EN ( pdf - 123 kB)
27 / 01 / 2012 - Paris (France)
Ipsen acknowledges Tanakan® delisting in France
PR Delisting Tanakan EN_0 ( pdf - 68 kB)
24 / 01 / 2012 - Paris (France)
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
PR Santhera Ipsen Fipamezole EN ( pdf - 49 kB)
23 / 01 / 2012 - Paris (France)
Fifth meeting in the “Biological Complexity” series jointly organised by the Fondation Ipsen and the Salk Institute for Biological Studies
20120123-PR Immunity and inflammation EN ( pdf - 29 kB)
05 / 01 / 2012 - Dijon and Paris (France)
Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target
PR Oncodesign Ipsen_EN ( pdf - 93 kB)
04 / 01 / 2012 - Paris (France)
Ipsen announces its corporate agenda for 2012
PR financial agenda_2012_EN ( pdf - 21 kB)
02 / 12 / 2011 - Paris (France)
The 20th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Patricia K. Kuhl (University of Washington, Seattle, USA)
20121202-PR Neuropsychology prize Patricia K Kuhl EN ( pdf - 31 kB)
29 / 11 / 2011 - Paris (France)
The 11st Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multiple origins of sex differences in brain. Neuroendocrine functions and their pathologies.”
20111129-PR Endocrinology sex differences in brain EN ( pdf - 32 kB)
28 / 11 / 2011 - Paris (France)
Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors
PR OBI-1 2nd phase III congenital hemophilia A EN ( pdf - 38 kB)
23 / 11 / 2011 - Paris (France)
16th Longevity Prize of La Fondation Ipsen: Professor Thomas Kirkwood is awarded in recognition of his outstanding leadership in the domain of “Theoretical approach to the biology of longevity”
20111123-PR Thomas Kirkwood 16th Longevity Prize_EN ( pdf - 27 kB)
02 / 11 / 2011 - Paris (France)
Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy
PR Sales Apokyn Britannia Pharmaceuticals_EN ( pdf - 54 kB)
27 / 10 / 2011 - Paris (France)
Ipsen’s first nine months of 2011 sales
PR Q3 2011 Sales_EN ( pdf - 106 kB)
20 / 10 / 2011 - Paris (France) and Oxford (UK)
Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics
PR Syntaxin Ipsen EN_0 ( pdf - 61 kB)
03 / 10 / 2011 - Paris (France)
Ipsen’s partner, Inspiration Biopharmaceuticals, announces acceptance of European marketing authorization application for IB1001 for the treatment of hemophilia B
PR Ipsen IB1001 EU approval filing FINAL EN ( pdf - 36 kB)
27 / 09 / 2011 - Paris (France)
Ipsen in-licenses from Photocure Hexvix®, the first approved & marketed drug for improved detection of bladder cancer, a key step in the surgical resection
PR Ipsen Hexvix EN ( pdf - 69 kB)
30 / 08 / 2011 - Paris (France)
Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer
PR Appointments COMEX_EN ( pdf - 32 kB)
30 / 08 / 2011 - Paris (France)
Ipsen’s half-year 2011 Results
PR Ipsen Results H1 2011 EN ( pdf - 291 kB)
Ipsen_H1_2011_results_0 ( pdf - 124 kB)
30 / 08 / 2011 - Paris (France) and Laguna Niguel (California, USA)
Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration’s Hemophilia Pipeline in Europe
PR Ipsen Inspiration EU Business Unit Hemophilia EN ( pdf - 49 kB)
28 / 07 / 2011 - Paris (France)
Ipsen’s partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23 rd ISTH congress
20110728 PR _Ipsen_OBI-1 ISTH EN ( pdf - 38 kB)
19 / 07 / 2011 - Paris (France)
22nd Neuronal Plasticity Prize of the Fondation Ipsen: Helen J. Neville, Isabelle Peretz and Robert J. Zatorre awarded for their pioneering research into the domain of “Music and Brain Plasticity”
20120719-PR_22nd Neuronal Plasticity Prize_EN ( pdf - 33 kB)
12 / 07 / 2011 - Paris and Villejuif (France)
Ipsen and Institut de cancérologie Gustave Roussy enter into a partnership agreement
20110712_PR_IGR_partnership_agreement_EN ( pdf - 47 kB)
12 / 07 / 2011 - Paris (France)
Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research
20110712 PR Ipsen_Salk EN ( pdf - 33 kB)
09 / 06 / 2011 - Paris (France)
Increase focus, invest to grow, leverage footprint: Ipsen’s new strategy
PR Strategy 2020 EN FINAL ( pdf - 40 kB)
Strategy day June 9, presentation ( pdf - 4 MB)
06 / 06 / 2011 - Paris (France)
Ipsen announces discontinuation of the development of Irosustat in monotherapy
PR Irosustat_EN ( pdf - 29 kB)
27 / 05 / 2011 - Paris (France)
Change within Ipsen’s Executive Committee
PR_Claire Giraut_EN ( pdf - 25 kB)
27 / 05 / 2011 - Paris (France)
Combined Shareholders’ Meeting of Ipsen S.A. held on 27 May 2011
PR_Ipsen_Post_Shareholders_meeting_052711_EN ( pdf - 21 kB)
11 / 05 / 2011 - Paris (France)
Appointment of Etienne de Blois as Ipsen’s Executive Vice-President, Human Resources
PR_EtiennedeBlois_EN_0 ( pdf - 27 kB)
10 / 05 / 2011 - Paris (France)
The 26th Colloque Médecine et Recherche of the Fondation Ipsen in the series Alzheimer Disease : “Protein Quality Control in Neurodegenerative Diseases”
20110510-PR_Fondation_Alzheimers Disease ( pdf - 59 kB)
03 / 05 / 2011 - Paris (France)
Ipsen’s first quarter 2011 sales
PR Q1 2011 sales Final EN ( pdf - 88 kB)
02 / 05 / 2011 - Paris (France)
Changes within Ipsen’s Executive Committee
02052011_PR_ST FB _EN ( pdf - 25 kB)
27 / 04 / 2011 - Paris (France)
The Ipsen Group publishes its 2010 Registration document
CP DDR2010 UK ( pdf - 29 kB)
19 / 04 / 2011 - Paris (France)
The 19th Colloque Médecine et Recherche of the Fondation Ipsen in the Neuroscience series: “Epigenetics, Brain and Behavior
20110419-PR_Fondation_Neurosciences_Epigenetics_Brain_Behavior ( pdf - 33 kB)
18 / 04 / 2011 - Paris (France)
Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology
PR_Ipsen_Active_Biotech_EN ( pdf - 44 kB)
09 / 03 / 2011 - Paris (France)
The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen’s Prior Approval Supplement application
20110309 PR Somatuline Depot EDI FINAL EN ( pdf - 42 kB)
02 / 03 / 2011 - Paris (France)
Ipsen’s 2010 results and 2011 sales objective
PR FY2010 Ipsen results ( pdf - 349 kB)
FY 2010 Results ( pdf - 173 kB)
25 / 02 / 2011 - Paris (France)
Ipsen and bioMérieux enter into a broad partnership in personalized medicine
PR Ipsen-bioMerieux Theranostics Partnership 20110225_EN ( pdf - 37 kB)
03 / 02 / 2011 - Paris (France)
Ipsen’s partner Inspiration Biopharmaceuticals announces non-inferiority of IB1001, its recombinant factor IX for Hemophilia B
PR Ipsen IB1001 PK FINAL ( pdf - 34 kB)
02 / 02 / 2011 - Paris (France)
Ipsen’s fourth quarter and full year 2010 sales and other significant developments
PR-Full Year 2010 Sales FINAL ( pdf - 104 kB)
Full_Year_2010_Sales_0 ( pdf - 74 kB)
23 / 12 / 2010 - Paris (France)
Ipsen announces its corporate agenda for 2011
PR_Ipsen corporate agenda 2011_EN ( pdf - 22 kB)
15 / 12 / 2010 - Paris (France)
Ipsen closes its BIM 23A760 trials
PR Ipsen - BIM 23A760 EN FINAL ( pdf - 39 kB)
02 / 12 / 2010 - Paris (France)
The 19th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Giacomo Rizzolati (University of Parma, Parma, Italy)
20101202-PR Neuropsychology prize Giacomo Rizzolati EN ( pdf - 31 kB)
30 / 11 / 2010 - Paris (France)
10th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multi-system Endocrine Disruption”
20101030-PR Multi-system endocrine disruption EN ( pdf - 36 kB)
23 / 11 / 2010 - Paris (France)
Professor Judith Campisi is awarded in recognition of the outstanding work she has been carrying in the domain of longevity, senescence and cancer
20121123-PR 15th Longevity Prize_EN ( pdf - 28 kB)
19 / 11 / 2010 - Paris (France)
Ipsen’s partner Inspiration Biopharmaceuticals announces the treatment of the first patient in phase III pivotal study of OBI-1 for acquired hemophilia A
PR Ipsen - OBI phase III EN Final_1 ( pdf - 38 kB)
28 / 10 / 2010 - Paris (France)
Ipsen first’s nine months of 2010 Sales
PR Sales Q3 2010 FINAL EN ( pdf - 126 kB)
19 / 10 / 2010 - Paris (France)
OBI-1 Receives Orphan Drug Designation in Europe
PR OBII-1 orphan drug status granted by EC FINAL EN ( pdf - 41 kB)
11 / 10 / 2010 - Paris (France)
Ipsen sells its shares in PregLem Holding SA to Gedeon Richter Plc
PR_PregLem_FINAL_EN ( pdf - 32 kB)
11 / 10 / 2010 - Paris (France)
Ipsen’s Board of Directors announces Jean-Luc Bélingard’s departure and the appointment of Marc de Garidel as new Chairman and CEO
PR-JL Belingard Marc de Garidel EN ( pdf - 34 kB)
11 / 10 / 2010 - Paris (France)
“Cell Biology in Recognition”
20101011-PR Biology of Recognition EN ( pdf - 28 kB)
03 / 09 / 2010 - Liestal (Switzerland) and Paris (France)
Santhera and Ipsen Enter into Licensing Agreement Santhera and Ipsen Enter into Licensing Agreement in Parkinson’s Disease
PR joint Santhera-Ipsen_fipamezole FINAL EN ( pdf - 79 kB)
31 / 08 / 2010 - Paris (France)
Ipsen’s Half-year 2010 Results
PR_H1_2010 Results_EN ( pdf - 232 kB)
Ipsen_H1_2010_Results_Presentation_0 ( pdf - 1 MB)
26 / 06 / 2010 - Paris (France)
Ipsen’s partner Roche confirms the promising efficacy profile of Taspoglutide
PR_Taspoglutide_Results_ADA_EN ( pdf - 85 kB)
22 / 06 / 2010 - Paris (France)
Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
PR GuidAge Results FINAL EN ( pdf - 90 kB)
18 / 06 / 2010 - Paris (France)
Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
PR Roche REM Taspoglutide EN FINAL ( pdf - 33 kB)
17 / 06 / 2010 - Paris (France) and Laguna Niguel (CA, USA)
OBI-1 developed by Ipsen and Inspiration has obtained a positive opinion for the orphan drug status in Europe
PR Inspiration OBI-1 EU orphan drug status EN FINAL_0 ( pdf - 43 kB)
09 / 06 / 2010 - Paris (France)
Implementation of a Sponsored Level I American Depositary Receipt (ADR) program: A new step in Ipsen’s development in the United States
PR ADR FINAL ( pdf - 27 kB)
28 / 05 / 2010 - Paris (France)
Combined Shareholders’ Meeting of Ipsen S.A. held on 28 May 2010
PR_Ipsen_Post_Shareholders_meeting_052810_EN ( pdf - 20 kB)
03 / 05 / 2010 - Paris (France)
Ipsen’s first quarter 2010 sales
03052010 PR Sales Q1 2010 ( pdf - 213 kB)
29 / 04 / 2010 - Paris (France)
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in a key phase III clinical trial
PR 29042010 TE-3 ( pdf - 35 kB)
27 / 04 / 2010 - Paris (France)
Ipsen and Invida Enter into a Partnership for the Commercialization of Ipsen’s Specialty Care Drugs in South-East Asia
27042010 PR Invida EN ( pdf - 62 kB)
30 / 03 / 2010 - Paris (France) and Watertown, Massachusetts (USA)
Dicerna Pharmaceuticals and Ipsen enter into an exclusive research collaboration for the development of new therapeutic agents in endocrinology and oncology
PR Dicerna Ipsen ( pdf - 49 kB)
24 / 03 / 2010 - Paris (France)
Update on Ipsen’s share capital structure
PR Mayroy EN ( pdf - 24 kB)
23 / 03 / 2010 - Paris (France) and Memphis (USA)
GTx and Ipsen expand partnership
PR GTx Ipsen Acapodene FINAL EN ( pdf - 50 kB)
15 / 03 / 2010 - Paris (France)
Initiation of two phase II studies with Ipsen’s proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors
PR BIM23A760 first patients NET & Acromegaly EN ( pdf - 33 kB)
12 / 03 / 2010 - Paris (France)
Ipsen grants Rhythm exclusive worldwide license for two programs in the field of metabolic disorders
12032010 PR Ipsen Rhythm Ghrelin MSH EN ( pdf - 74 kB)
05 / 03 / 2010 - Paris (France)
Launch by Menarini and Ipsen of ADENURIC® (febuxostat) in France for the treatment of chronic hyperuricemia in gout
PR Menarini Ipsen Launch Adenuric EN ( pdf - 61 kB)
04 / 02 / 2010 - Paris (France)
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
PR DKP 6 months launch France EN ( pdf - 88 kB)
01 / 02 / 2010 - Paris (France)
Ipsen’s fourth quarter and full year 2009 sales
PR Q4 2009 Sales FINAL ( pdf - 113 kB)
21 / 01 / 2010 - Paris (France) and Laguna Niguel (CA, USA)
Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise
Prez Press & internal EN ( pdf - 1 MB)
PR Inspiration EN ( pdf - 67 kB)
17 / 12 / 2009 - Paris (France)
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus®) and versus placebo in patients with high body mass index (BMI)
PR Emerge5 phase III results EN FINAL ( pdf - 34 kB)
17 / 12 / 2009 - Paris (France)
Ipsen’s financial communication nominated to the “2009 Trophy of the Best Investor Relations” of Euronext
20091217_investor_update_ir_award_2009_EN ( pdf - 25 kB)
14 / 12 / 2009 - Paris (France)
Ipsen establishes optimal biological dose for BN83495 steroid sulphatase (STS) inhibitor in ER-positive metastatic breast cancer
PR BN83495 Breast cancer Phase I EN FINAL ( pdf - 40 kB)
09 / 12 / 2009 - Paris (France)
Ipsen announces its corporate agenda for 2010
20091209_ipsen_announces_its_corporate_agenda_EN ( pdf - 23 kB)
02 / 12 / 2009 - Paris (France)
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo
PR Emerge1&4 phase III results EN FINAL ( pdf - 34 kB)
25 / 11 / 2009 - Paris (France)
Ipsen initiates an Advanced Endometrial Cancer program with BN83495, its first-in-class steroid sulfatase (STS) inhibitor
20091125___bn83495_phase_ii_10 ( pdf - 30 kB)
13 / 11 / 2009 - Paris (France)
Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer
20091113___amm_decapeptyl_france_10 ( pdf - 79 kB)
29 / 10 / 2009 - Paris (France)
Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia
20091029___launch_dysport_us_10 ( pdf - 48 kB)
29 / 10 / 2009 - Paris (France)
Ipsen’s first nine months of 2009 sales and update of Group financial objectives
20091029___q3_2009_10 ( pdf - 100 kB)
29 / 10 / 2009 - Paris (France)
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial
20091029___taspoglutide_phase_iii_10 ( pdf - 33 kB)
20 / 10 / 2009 - Paris (France)
Ipsen grants Menarini exclusive European licence rights to Adenuric® (febuxostat), its novel treatment for chronic hyperuricaemia in gout
20091019___adenuric_menarini_10 ( pdf - 68 kB)
13 / 10 / 2009 - Lausanne (Switzerland) and Paris (France)
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer.
20091013___decapeptyl_6_months_10 ( pdf - 88 kB)
09 / 10 / 2009 - Braintree (Massachusetts, United States) and Paris (France)
Ipsen acquires exclusive marketing rights of BLI-800 from Braintree for colonic cleansing before colonoscopy
20091009___braintree_bli_800_10 ( pdf - 44 kB)
08 / 10 / 2009 - Paris (France) and London (United Kingdom)
Ipsen and Spirogen redesign their collaboration for the development of SJG-136 (now SG2000)
20091008___spirogen_sjg_136_10 ( pdf - 55 kB)
22 / 09 / 2009 - Paris (France)
Appointment of Claude Bertand as Executive Vice President, Chief Scientific Officer of Ipsen. Jacques-Pierre Moreau is appointed Chief Scientific Advisor to the Executive Committee.
20090921___nomination_claude_bertrand_10 ( pdf - 28 kB)
21 / 09 / 2009 - Lausanne (Switzerland) and Paris (France)
AZZALURE® approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
20090921_azzalure_approved_in_spain_10 ( pdf - 45 kB)
15 / 09 / 2009 - Paris (France)
Encouraging preliminary new data available for the treatment of short stature children with low IGF-1 levels.
20090915___espe_new_york_10 ( pdf - 36 kB)
07 / 09 / 2009 - Paris (France) and Lausanne (Switzerland)
Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major human cancers.
20090907___debiopharm_ipsen_cdc25_10 ( pdf - 39 kB)
28 / 08 / 2009 - Paris (France)
Ipsen’s half year 2009 results
20090827___results_h1_09_12 ( pdf - 918 kB)
20090827___results_h1_09_10 ( pdf - 700 kB)
16 / 07 / 2009 - Paris (France)
Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels
20090716___resultats_bim23a760_10 ( pdf - 40 kB)
26 / 06 / 2009 - Paris (France) and Lausanne (Switzerland)
Azzalure approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
20090626___azzalure_allemagne_10 ( pdf - 48 kB)
15 / 06 / 2009 - Paris (France)
Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement
20090615___ipsen_pharnext_10 ( pdf - 51 kB)
04 / 06 / 2009 - Paris (France)
Ipsen’s Annual Shareholders’ Meeting on June 4, 2009
20090609___cr_ag_10 ( pdf - 19 kB)
20 / 05 / 2009 - Paris (France)
Combined General Meeting on June 4, 2009 – Availability of preliminary documents
20090520___documents_ag_2009_10 ( pdf - 21 kB)
19 / 05 / 2009 - Paris (France)
Disclosure of trading in own shares
20090519___disclosure_of_trading_in_own_shares_10 ( pdf - 34 kB)
14 / 05 / 2009 - Paris (France)
Disclosure of trading in own shares
20090514___rachat_d_actions_10 ( pdf - 22 kB)
11 / 05 / 2009 - Paris (France)
Appointment of Jean-Christophe Tellier as President and General manager of Ipsen in North America
20090511___appointment_jc_tellier_10 ( pdf - 35 kB)
30 / 04 / 2009 - Scottsdale (Arizona, USA) and Paris (France)
FDA approves Dysport(TM) for therapeutic and aesthetic uses
20090430___dysport_usa_10 ( pdf - 81 kB)
28 / 04 / 2009 - Paris (France)
Ipsen’s first quarter 2009 sales and financial outlook for the full year
20090428___q1_2009_10 ( pdf - 82 kB)
20 / 04 / 2009 - Paris (France)
Mise à disposition du document de référence 2008
20090420_drf2008 ( pdf - 31 kB)
14 / 04 / 2009 - Paris (France) and Scottsdale (Arizona, USA)
Update on Ipsen’s botulinum toxin type A product regulatory review status in the US
20090428___q1_2009_10 ( pdf - 82 kB)
31 / 03 / 2009 - Lausanne (Switzerland) and Paris (France)
AZZALURE® is approved in France for Aesthetic Use in the Treatment of Frown Lines
20090331___azzalure_amm_france_10 ( pdf - 39 kB)
12 / 03 / 2009 - Lausanne (Switzerland) and Paris (France)
AZZALURE® approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
20090312___azzalure_uk_10 ( pdf - 47 kB)
02 / 03 / 2009 - Paris (France)
Ipsen’s full year 2008 results
20090301___resultats_2009_12 ( pdf - 1 MB)
20090301___resultats_2009_10 ( pdf - 162 kB)
24 / 02 / 2009 - Paris (France)
Christian de la Tour is promoted Chairman of Ipsen UK and Sean McKercher, Vice-President, Corporate Business Development
20090224___sean_mckercher___c_de_la_tour_10 ( pdf - 25 kB)
02 / 02 / 2009 - Paris (France) and Lausanne (Switzerland)
The Health Authorities of 15 European countries give a collective green light to Azzalure® for the treatment of glabellar lines, paving the way for national marketing authorizations
20090202___azzalure_green_vert_10 ( pdf - 40 kB)
29 / 01 / 2009 - Paris (France)
Ipsen’s full year 2008 sales
20090129___full_year_2008_sales_10 ( pdf - 96 kB)
28 / 01 / 2009 - Paris (France)
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge® in France
20090128___co_promotion_agreement_with_novartis_10 ( pdf - 64 kB)
19 / 01 / 2009 - Paris (France)
“Creating the future: New challenges in biology and medicine”: Ipsen gathers a panel of world-renowned scientists
20090119___symposium_creating_the_future_12 ( pdf - 2 MB)
20090119___symposium_creating_the_future_10 ( pdf - 47 kB)
20090119___symposium_creating_the_future_14 ( pdf - 628 kB)
08 / 01 / 2009 - Paris (France)
Ipsen provides update on R&D pipeline and business opportunities at its Investor Day
20090108___investor_day_10 ( pdf - 59 kB)
07 / 01 / 2009 - Paris (France)
FDA’s first-cycle review of Reloxin® extended
20090107___extension_de_la_periode_d_examen_de_reloxin_10 ( pdf - 50 kB)
05 / 01 / 2009 - Paris (France)
Ipsen announces its corporate agenda for 2009
20090105___financial_calendar_10 ( pdf - 26 kB)
29 / 12 / 2008 - Paris (France)
FDA issues Complete Response Letter to Ipsen for Dysport® Biologics License Application
20081229___dysport_response_letter_10 ( pdf - 36 kB)
12 / 12 / 2008 - Paris (France)
AFEP/MEDEF recommendations on compensation of executive directors
20081212___afep_medef_recommendations_on_compensation_10 ( pdf - 25 kB)
30 / 10 / 2008 - Paris (France)
Ipsen’s first nine months of 2008 sales and update of Group financial objectives
20081030___results_q3_10 ( pdf - 94 kB)
17 / 10 / 2008 - Paris (France)
Ipsen completes the acquisition of Tercica, Inc. in North America, the third of its three steps to globalize its fast growing specialist care business
20081017___tercica_closing_10 ( pdf - 49 kB)
30 / 09 / 2008 - Paris (France)
FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track
20080930___dysport_pdufa_10 ( pdf - 49 kB)
25 / 09 / 2008 - Paris (France)
Ipsen announces the filing of Decapeptyl® 6-month formulation for the treatment of locally advanced or metastatic prostate cancer in Europe
20080925___eu_filing_of_decapeptyl_6_month_formulation_10 ( pdf - 52 kB)
29 / 08 / 2008 - Paris (France)
Ipsen’s half year 2008 results and update on standalone financial objectives for the full year 2008
20080829___results_h1_2008_10 ( pdf - 222 kB)
20080829_ipsen_s_half_year_2008_results_and_update_on_standalone_financial_objectives_for_the_full_year_2008_15 ( pdf - 3 MB)
31 / 07 / 2008 - Paris (France)
Ipsen’s first half 2008 sales, outlook for the full year 2008 and R&D pipeline update
20080731___q2_sales_2008_10 ( pdf - 93 kB)
23 / 07 / 2008 - Paris (France)
Ipsen continues the acquisition process of Tercica so as to establish its global presence in endocrinology
20080717_closing_octagen ( pdf - 49 kB)
17 / 07 / 2008 - Paris (France)
Ipsen completes purchase of all of OBI-1 assets from Octagen Corporation
20080717_closing_octagen ( pdf - 49 kB)
01 / 07 / 2008 - Paris (France)
Ipsen completes purchase of Apokyn®, Vernalis US commercial operations and share subscription
20080701_closing_vernalis ( pdf - 47 kB)
10 / 06 / 2008 - Paris (France) and Basel (Switzerland)
Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials
20080610_ipsen_roche_phase_iii ( pdf - 110 kB)
05 / 06 / 2008 - Paris (France)
Ipsen builds a fully fledged presence in North America, significantly enhancing its geographic footprint, global specialty portfolio and growth profile
20080605_ipsen_in_north_america ( pdf - 90 kB)
04 / 06 / 2008 - Paris (France)
Ipsen’s Annual Shareholders’ Meeting on 4 June 2008
20080604_crendu_ag ( pdf - 33 kB)
02 / 06 / 2008 - Paris (France) and London (United Kingdom)
Ipsen and Spirogen’s SJG-136 shows encouraging results in the treatment of refractory solid tumours at ASCO
20080602_pr_spirogen_sjg136_phase_i ( pdf - 57 kB)
22 / 05 / 2008 - Paris (France)
Appointment of Gérard Picot as Vice President, Global Regulatory Affairs
20080522_nomination_gpicot ( pdf - 28 kB)
19 / 05 / 2008 - Paris (France) and Scottsdale, Arizona (United States)
Ipsen and Medicis announce acceptance of Reloxin® BLA in aesthetics by FDA
20080519_acceptance_of_reloxin_bla ( pdf - 297 kB)
05 / 05 / 2008 - Paris (France)
Adenuric® (febuxostat) receives marketing authorisation in the European Union
20080505_autorisation_adenuric_eu ( pdf - 80 kB)
29 / 04 / 2008 - Paris (France)
Ipsen’s first quarter 2008 sales
20080428_resultats_t1_2008 ( pdf - 69 kB)
01 / 04 / 2008 - Paris (France)
Appointment of Dominique Bridon, PhD as Vice President, Discovery
20080401_nomination_dominique_bridon ( pdf - 28 kB)
18 / 03 / 2008 - Paris (France)
Appointment of Frédéric Babin as Executive Vice President, Human Resources
20080318_nomination_frederic_babin ( pdf - 28 kB)
17 / 03 / 2008 - Paris (France) and Scottsdale, Arizona (United States)
Ipsen and Medicis announce submission of Reloxin® BLA in aesthetics to the FDA
20080317_soumission_reloxin ( pdf - 305 kB)
27 / 02 / 2008 - Paris (France)
Ipsen’s full year 2007 results and financial objectives for the full year 2008
20080227_resultats_2007 ( pdf - 205 kB)
25 / 02 / 2008 - Paris (France)
Toremifene citrate 80 mg meets primary and key secondary endpoints in phase III clinical trial in advanced prostate cancer patients on androgen deprivation therapy
20080225_acadopene_phase_iii ( pdf - 32 kB)
21 / 02 / 2008 - Paris (France)
EMEA recommends marketing authorisation of Ipsen’s Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout
20080221_febuxostat_opinion_positive ( pdf - 58 kB)
12 / 02 / 2008 - Paris (France)
Clinical update for Decapeptyl® 6-month formulation in advanced prostate cancer
20080212_resultats_decapeptyl ( pdf - 31 kB)
31 / 01 / 2008 - Paris (France)
Ipsen’s Full Year 2007 sales
20080131_md_a_sales_q4_2007 ( pdf - 79 kB)
31 / 01 / 2008 - Paris (France)
FDA accepts for filing a Biologics License Application (BLA) for Dysport® in cervical dystonia
20080131_mise_sur_le_marche_de_dysport_aux_us ( pdf - 26 kB)
11 / 01 / 2008 - Paris (France)
Ipsen and The Salk Institute Enter into Strategic Research Agreement
20080111_salk_institute ( pdf - 1 MB)
03 / 01 / 2008 - Paris (France)
Two years after its IPO, Ipsen enters the SBF 120 index
20080103_sbf_120 ( pdf - 27 kB)
20 / 12 / 2007 - Paris (France)
Ipsen announces its corporate agenda for 2008
20071220___corporate_agenda_for_2008_10 ( pdf - 22 kB)
06 / 12 / 2007 - Paris (France)
Ipsen submits a Biologics License Application (BLA) in cervical dystonia to the FDA for Dysport®
20071206___dysport_bla_to_fda_10 ( pdf - 25 kB)
06 / 12 / 2007 - Paris (France) and Lausanne (Switzerland)
Ipsen grants Galderma exclusive rights to promote and distribute Dysport® in aesthetic medicine and dermatological indications in Brazil, Argentina and Paraguay
20071206___ipsen_galderma_10 ( pdf - 3 MB)
06 / 12 / 2007 - Paris (France) et Scottsdale (Etats-Unis)
Ipsen and Medicis announce submission of Reloxin® in aesthetics to the FDA
20071206___ipsen_medicis_10 ( pdf - 333 kB)
04 / 12 / 2007 - Paris (France)
Seventh Colloque Médecine et Recherche of La Fondation Ipsen in the Endocrinology series: “Hormones and Social Behaviour”
20071204___colloque_fondation_10 ( pdf - 34 kB)
04 / 12 / 2007 - Paris (France)
New Collaboration between Ipsen and Erasmus MC in endocrinology
20071204___ipsen_erasmus_10 ( pdf - 27 kB)
20 / 11 / 2007 - Paris (France) and Alameda (California, USA)
Celera and Ipsen enter research collaboration to develop pharmacogenomic tests
20071120___ipsen_celera_10 ( pdf - 37 kB)
31 / 10 / 2007 - Paris (France)
Ipsen and Debiopharm extend their agreement for the exclusive commercialization of Decapeptyl® (triptorelin pamoate) in Europe and certain other territories
20071031_ipsen_debiopharm ( pdf - 43 kB)
17 / 09 / 2007 - Marcy l'Etoile and Paris (France)
bioMérieux and Ipsen sign theragnostics agreement to develop companion test for New breast cancer treatment
20070917_ipsen_biomerieux ( pdf - 35 kB)
17 / 09 / 2007 - Paris (France)
A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005
20070917_radius_and_novartis ( pdf - 24 kB)
31 / 08 / 2007 - Paris (France)
Somatuline® Depot receives marketing approval in the United States for the treatment of acromegaly
20070831_us_ma_somatuline ( pdf - 32 kB)
29 / 08 / 2007 - Paris (France)
Ipsen’s first half 2007 results and financial objectives for the full year 2007
20070829_h1_2007_results ( pdf - 147 kB)
23 / 08 / 2007 - Paris (France)
Ipsen transfers Ginkor Fort® marketing authorisations to GTF for France, Monaco and Andorra
20070823_ipsen_gtf ( pdf - 30 kB)
09 / 08 / 2007 - Paris (France)
Increlex® receives marketing authorisation in the European Union
20070809_marketing_authorisation_increlex ( pdf - 45 kB)
01 / 08 / 2007 - Paris (France)
First half 2007 sales and outlook for the second half 2007
20070801_first_half_2007_sales ( pdf - 80 kB)
27 / 06 / 2007 - Paris (France)
Ipsen announces license agreement with PregLem SA in field of reproductive medicine
20070627_ipsen_and_preglem ( pdf - 26 kB)
11 / 06 / 2007 - Paris (France)
Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
20070611_arret_phase_iii_decapeptyl ( pdf - 28 kB)
06 / 06 / 2007 - Paris (France)
Ipsen’s Annual Shareholders’ Meeting on 6 June 2007
20070606_annual_shareholders_meeting_2007 ( pdf - 39 kB)
01 / 06 / 2007 - Paris (France)
Ipsen will invest €55 million and plans to create 85 new jobs in Dreux (France) by 2011
20070601_dreux_investment ( pdf - 38 kB)
25 / 05 / 2007 - Paris (France)
Increlex® receives CHMP positive opinion for the treatment of severe primary IGF-1 deficiency
20070525_increlex_receives_chmp_positive_opinion ( pdf - 49 kB)
03 / 05 / 2007 - Paris (France)
Ipsen’s first quarter 2007 sales
20070503_first_quarter_2007_sales ( pdf - 162 kB)
06 / 04 / 2007 - Paris (France)
Ipsen appoints Sean McKercher as Vice President of Commercial Development in North America
20070416_sean_mckercher_appointment ( pdf - 28 kB)
03 / 04 / 2007 - Paris (France)
Appointment of Eric Drapé as Executive Vice President, Manufacturing and Supply Organisation
20070403_eric_drape_appointment ( pdf - 31 kB)
19 / 03 / 2007 - Paris (France)
Ipsen’s full year 2006 results
20070319_2006_results ( pdf - 952 kB)
26 / 02 / 2007 - Paris (France)
Ipsen grants Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product for aesthetic indications in Europe and certain other territories
20070226_agreement_with_galderma_in_aesthetics ( pdf - 3 MB)
26 / 02 / 2007 - Paris (France)
Appointment of Stéphane Thiroloix as Executive Vice-President, Corporate Development
20070226_stephane_thiroloix_appointment ( pdf - 26 kB)
01 / 02 / 2007 - Paris (France)
Ipsen’s Full Year 2006 Sales
20070201_full_year_2006_sales ( pdf - 181 kB)
30 / 01 / 2007 - Paris (France)
Agreement between Ipsen and MSD for the co-marketing in France of AdrovanceTM for the treatment of postmenopausal osteoporosis
20070130_agreement_with_msd_for_adrovancetm ( pdf - 85 kB)
24 / 01 / 2007 - Paris (France)
Ipsen strikes alliance with the Erasmus University Medical Centre Rotterdam
20070124_erasmus_university_mc_rotterdam ( pdf - 33 kB)
15 / 01 / 2007 - Paris (France)
FDA accepts for filing a New Drug Application (NDA) for Somatuline® Autogel® – Somatuline® Autogel® now available in Canada
20070115_fda_accepts_for_filing_a_nda_for_somatuline__autogel ( pdf - 27 kB)
14 / 12 / 2006 - Paris (France)
Initiation of phase III clinical trials with Decapeptyl®’s 4-month sustained release formulation
20061214_decapeptyl_4_mois_debut_phase_3 ( pdf - 57 kB)
19 / 10 / 2006 - Paris (France)
Ipsen has noted the publication of the recommendations issued by the French Haute Autorité de Santé
20061019_recommendations_has ( pdf - 47 kB)
16 / 10 / 2006 - Paris (France)
Ipsen and Tercica Complete Worldwide Strategic Collaboration Agreement in Endocrinology
20061016_ipsen_and_tercica ( pdf - 64 kB)
02 / 10 / 2006 - Paris (France)
EMEA’s validation of febuxostat’s Marketing Authorization Application in the European Union
20061002_emea_validation_of_febuxostat ( pdf - 30 kB)
30 / 09 / 2006 - Paris (France)
Ipsen’s first nine months of 2006 sales
20060930_first_9_months_2006 ( pdf - 261 kB)
07 / 09 / 2006 - Paris (France)
Ipsen and GTx enter into partnership agreement for the European rights of Acapodene®
20060907_ipsen_and_gtx ( pdf - 54 kB)
06 / 09 / 2006 - Paris (France)
Ipsen’s first half 2006 results
20060906_first_6_months_2006_results ( pdf - 921 kB)
01 / 08 / 2006 - Paris (France)
Ipsen’s first half 2006 sales
20060801_first_half_2006_sales ( pdf - 214 kB)
19 / 07 / 2006 - Paris (France) and Basel (Switzerland)
Roche exercises its option on Ipsen’s anti-diabetic medicine for type 2 diabetes
20060719_ipsen_and_roche_bim51077 ( pdf - 43 kB)
19 / 07 / 2006 - Paris (France)
Ipsen and Tercica to enter into worldwide strategic collaboration in endocrinology
20060719_ipsen_and_tercica ( pdf - 158 kB)
12 / 07 / 2006 - Paris (France) and Scottsdale (USA)
Medicis and Ipsen decide to focus partnership for Reloxin® exclusively on USA, Canada and Japan
20060712_ipsen_and_medicis ( pdf - 58 kB)
12 / 06 / 2006 - Paris (France)
Type 2 diabetes therapy: Ipsen is currently testing an innovative sustained release formulation of its GLP-1 analogue based on its proprietary drug delivery system technologies
20060612_type2_diabete ( pdf - 63 kB)
02 / 06 / 2006 - Paris (France)
Ipsen’s Annual Shareholders’ Meeting on 2 June 2006
20060602_ipsen_annual_shareholders_2006 ( pdf - 34 kB)
02 / 05 / 2006 - Paris (France)
Ipsen reports sales growth of 10.2% at 31st March 2006
20060502_ipsen_reports_sales_growth_at_31st_march_2006 ( pdf - 126 kB)
19 / 04 / 2006 - Paris (France)
David Schilansky joined Ipsen as Investor Relations Officer
20060419_david_schilansky ( pdf - 42 kB)
16 / 04 / 2006 - Paris (France)
Ipsen extends the deadline for entering into its European agreement with Medicis
20060416_ipsen_and_medicis ( pdf - 26 kB)
20 / 03 / 2006 - Paris (France) and Scottsdale (USA)
Reloxin® agreement between Ipsen and Medicis becomes effective
20060320_ipsen_reloxin_with_medicis ( pdf - 48 kB)
17 / 03 / 2006 - Paris (France)
Ipsen announces 26.4% increase in 2005 consolidated net profit
20060317_ipsen_announces_increase ( pdf - 648 kB)
13 / 03 / 2006 - Paris (France)
Ipsen chooses Medicis to promote and distribute Ipsen’s botulinum toxin product to the aesthetic market
20060313_ipsen_chooses_medicis ( pdf - 49 kB)
07 / 02 / 2006 - Paris (France)
Jean-Luc Bélingard, member of the Board of Directors of Inserm
20060207_jean_luc_belingard_inserm ( pdf - 52 kB)
01 / 02 / 2006 - Paris (France)
Ipsen reports full-year sales growth of 7.4% in the year ended 31 December 2005 (unaudited)
20060201_ipsen_full_year_sales_report_2005 ( pdf - 175 kB)